Evolution of the Antidepressant Prescribing in Alzheimer's Disease and Related Disorders Between 2010 and 2014: Results from the French National Database on Alzheimer's Disease (BNA).

BACKGROUND Safety warnings from health authorities are currently intended to limit the use of psychotropic agents in dementia-related conditions. Evidence concerning the use of antidepressants in dementia is, however, scarce and contradictory. OBJECTIVE To evaluate antidepressant use among individuals with Alzheimer's disease (AD) and related disorders in the French population between 2010 and 2014. METHOD Antidepressant prescriptions in individuals with AD, mixed dementia (MD), and vascular dementia (VaD) in the French National Alzheimer Database between 2010 and 2014 were analyzed (N = 199,544). RESULTS Multivariate analysis showed an annual significant increase (p < 0.001) in the prescription rate of antidepressants from 26% (2010) to 31% (2014), and identified female gender, younger age, higher education, living in long-term facilities, more severe cognitive decline, and presence of vascular signs (VaD and MD) as associated factors for antidepressant prescribing. CONCLUSION The annual increase of antidepressant prescribing among individuals with AD, MD, and VaD in French specialized settings may be partially related to the lack of current valuable medications for dementia-related behavioral symptoms.

[1]  K. Langa,et al.  Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA , 2017, International journal of geriatric psychiatry.

[2]  P. Robert,et al.  Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home. , 2015, Journal of Alzheimer's disease : JAD.

[3]  Kaarin J Anstey,et al.  Dementia risk estimates associated with measures of depression: a systematic review and meta-analysis , 2015, BMJ Open.

[4]  L. Simoni-Wastila,et al.  Treated Behavioral Symptoms and Mortality in Medicare Beneficiaries in Nursing Homes with Alzheimer's Disease and Related Dementias , 2015, Journal of the American Geriatrics Society.

[5]  A. Tanskanen,et al.  High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort , 2014, European Neuropsychopharmacology.

[6]  J. Sundquist,et al.  Neighborhood linking social capital as a predictor of psychiatric medication prescription in the elderly: a Swedish national cohort study. , 2014, Journal of psychiatric research.

[7]  S. Bonin-Guillaume,et al.  Consommation d’antipsychotiques chez les sujets atteints de maladie d’Alzheimer et maladies apparentées de la cohorte PACA-Alz 2010 , 2014 .

[8]  J. Neuhaus,et al.  Demographic and Neuropsychiatric Factors Associated With Off-label Medication Use in Frontotemporal Dementia and Alzheimer’s Disease , 2014, Alzheimer disease and associated disorders.

[9]  Christine Leong.  Antidepressants for depression in patients with dementia: a review of the literature. , 2014, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[10]  S. Fereshtehnejad,et al.  Anti-Dementia Drugs and Co-Medication Among Patients with Alzheimer’s Disease , 2014, Drugs & Aging.

[11]  Susan G. Brown,et al.  Psychotropic and Cognitive-Enhancing Medication Use and Its Documentation in Contemporary Long-term Care Practice , 2014, The Annals of pharmacotherapy.

[12]  P. Rosenberg,et al.  Pharmacotherapeutic Management of Dementia Across Settings of Care , 2013, Journal of the American Geriatrics Society.

[13]  M. Orrell,et al.  Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. , 2013, Health technology assessment.

[14]  J. Nuyen,et al.  The diagnosis of depression and use of antidepressants in nursing home residents with and without dementia , 2013, International journal of geriatric psychiatry.

[15]  C. Martinez,et al.  Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study , 2013, BMJ Open.

[16]  E. Englund,et al.  History of depression prior to Alzheimer's disease and vascular dementia verified post-mortem. , 2013, Archives of gerontology and geriatrics.

[17]  P. Zandi,et al.  The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease , 2012, International journal of geriatric psychiatry.

[18]  Pamela C. Heaton,et al.  Impact of the Food and Drug Administration’s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings , 2012, Alzheimer's & Dementia.

[19]  P. Robert,et al.  The 2008-2012 French Alzheimer plan: description of the national Alzheimer information system. , 2012, Journal of Alzheimer's disease : JAD.

[20]  P. Robert,et al.  Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort , 2012, The journal of nutrition, health & aging.

[21]  A. Iorio,et al.  Prevalence and characteristics of antidepressant drug prescriptions in older Italian patients , 2011, International Psychogeriatrics.

[22]  J. Shega,et al.  Psychotropic Medication Burden and Factors Associated with Antipsychotic Use: An Analysis of a Population‐Based Sample of Community‐Dwelling Older Persons with Dementia , 2011, Journal of the American Geriatrics Society.

[23]  U. Mosimann,et al.  Psychotropic medication use in Swiss nursing homes. , 2011, Swiss medical weekly.

[24]  B. Vellas,et al.  Antidepressant use in Alzheimer's disease patients: results of the REAL.FR cohort , 2009, International Psychogeriatrics.

[25]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.